COLLEGIUM PHARMACEUTICAL, INC (COLL) Q3 2025 10-Q Quarterly Report
COLLEGIUM PHARMACEUTICAL, INC (COLL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
COLLEGIUM PHARMACEUTICAL, INC Q3 2025 10-Q Analysis
Risk Factors
- • New FDA opioid labeling requirements effective July 31, 2025 mandate safety changes including overdose info, increasing compliance costs and marketing challenges
- • Most updated risk: $581.3M 2024 Term Loan and $241.5M 2029 Convertible Notes increase financial leverage and interest rate exposure via SOFR-linked variable rates
- • Regulatory risk: September 2025 FDA intensified enforcement on direct-to-consumer advertising increases risk of sanctions for non-compliant product promotions
- • Operational risk: sole supplier reliance for API manufacturing risks production disruptions impacting near-term product availability and costs
- • Financial risk: 2024 Loan Agreement covenants limit additional debt, acquisitions, and risk triggering default with asset foreclosure potential
Get deeper insights on COLLEGIUM PHARMACEUTICAL, INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.